While clinical studies have focused predominantly on the use of CDK4/6 inhibitors to treat endocrine-resistant breast cancer [60, 61], and use of CDK2/1 inhibitors has also been considered [42, 62]. This evidence concerns the gene CDK4 and breast carcinoma.